Quarter Comparison
Revenue
Operating Income
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular collaboration with Bris
EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb — SAN DIEGO, August 13, 2026 / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics,” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). “Our team continues to execute well, achie...
Source
Exhibit EX-99.1
0001193125-26-349482
Filed August 13, 2026 at 8:50 PM UTC. The figures above are from the audited statements, not from this release.